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Infection of macaques with chimeric simian/human immunodeficiency virus (SHIV) expressing the envelope protein of
HIV-1 provides a model system for studying HIV-1 infection in humans. To this end, four rhesus macaques (Macaca mulatta)
were given a single intravaginal (IVAG) inoculation of cell-free SHIVSF33A and longitudinal samples of peripheral blood and
lymph nodes were analyzed for viremia, antigenemia, and various T-cell populations. Rhesus macaques infected IVAG with
SHIVSF33A demonstrated a dramatic decrease in the CD4
1 PBMC subset in the initial weeks after viral exposure, a time that
corresponded to peak in plasma viremia and antigenemia. Within 4 months of SHIVSF33A inoculation, partial to complete
rebound of the CD41 PBMC was seen in these animals. Notably, the regeneration of the CD41 subset was associated with
regeneration of the naive T-cell population and was concordant with clearance of plasma viremia. DNA heteroduplex tracking
assays revealed transmission of minor variants within the SHIVSF33A inoculum to the IVAG-inoculated animals. The cell-free
SHIVSF33A inoculum as well as virus isolated from animals early after transmission used the chemokine molecule CXCR4 as
the primary cellular coreceptor, demonstrating that viruses expressing envelope glycoproteins of the syncytia inducing (SI)
phenotype can be transported across the vaginal mucosa. Although none of the animals has yet to develop clinical symptoms
of simian AIDS (SAIDS), infectious virus and viral nucleic acids could be persistently isolated from each animal. Furthermore,
animals transfused with blood from IVAG-infected macaques drawn 2 weeks after inoculation suffered a more profound and
sustained CD41 T-cell loss, persistent plasma viremia, and the development of SAIDS in one animal, indicating that
IVAG-passaged SHIVSF33A was pathogenic. Taken together, these results establish that a pathogenic CXCR4-utilizing
SHIVSF33A species crossed the cervicovaginal mucosa. Different courses of infection in the IVAG versus transfusion animals
suggest that host-mediated responses elicited upon transmission across mucosal barriers may serve to limit viral replication
and delay disease progression in the IVAG-infected animals. © 1998 Academic Press
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INTRODUCTION
Sexual transmission of the human immunodeficiency
virus type 1, HIV-1, is the primary mode of viral transmis-
sion causing the epidemic spread of AIDS (Joint United
Nations Programme on HIV/AID, 1996; Royce et al., 1997).
During transmission, cell-free virus and/or virally infected
cells present within genital fluids are deposited on re-
cipient mucosal surfaces to initiate infection (Borzy et al.,
1988; Vogt et al., 1986; Wofsy et al., 1986; Zagury et al.,
1984). However, the specific mechanisms involved in
sexual transmission, including the initial host cell used
for entry, selection of transmitted viral species, and im-
mune responses near the site of primary infection, are
still unclear. Because of the difficulties in studying HIV-1
transmission in the natural host, researchers have relied
on the simian immunodeficiency virus (SIV)/rhesus ma-
caque animal system as a paradigm for investigating
HIV-1 infection in humans (Desrosiers, 1988; Fultz, 1993;
Miller, 1994; Spira et al., 1996; Trivedi et al., 1994). The
ability to control the strain, amount, and route of inocu-
lation, and to obtain multiple samples at precise intervals
early after virus exposure, makes this model well suited
to study both viral transmission and acute infection. As a
result, the SIV/macaque animal model has played a cen-
tral role in understanding both viral transmission and
pathogenesis. Additionally, this system has been em-
ployed in the evaluation of vaccine strategies. Although,
this animal model has proven to be useful for studying
issues related to viral dissemination and pathogenesis,
the genetic, structural, and antigenic differences be-
tween the HIV-1 and SIV envelope proteins limit the utility
of the SIV/macaque model when examining envelope-
related issues including cellular tropism/coreceptor uti-
lization, antibody neutralization, and immune driven vari-
ation. To overcome this concern, chimeric clones of sim-
ian/human immunodeficiency virus (SHIV) that contain
the HIV-1 env coding sequence on the background of the
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SIV genome were developed (Li et al., 1992; Luciw et al.,
1995; Reimann et al., 1996b; Shibata et al., 1990). Al-
though, a number of enveloped chimeric viruses have
been demonstrated to be infectious by intravenous (iv),
oral, and genital routes of transmission, these SHIVs
have an attenuated pathogenesis in rhesus macaques
when compared to the parental SIV isolates (Li et al.,
1992; Lu et al., 1996; Luciw et al., 1995; Reimann et al.,
1996b; Sakuragi et al., 1992; Shibata et al., 1990).
Recently, several investigators have described the in
vivo derivation of pathogenic SHIV variants by passage
and adaptation in macaques (Joag et al., 1997b; Joag et
al., 1996; Karlsson et al., 1997; Reimann et al., 1996a;
Shibata et al., 1997). In one study, serial passage of bone
marrow from a pig-tailed macaque originally infected
with SHIV4 (containing the env gene from HIV-1HxB2)
resulted in the evolution of a virulent strain, SHIVKU-1, that
caused CD41 cell loss and SAIDS in infected animals
(Joag et al., 1997b; Joag et al., 1996). Cell-free inoculation
of SHIVKU-1 iv or intravaginally (IVAG) into pig-tailed ma-
caques caused systemic and CNS infection, severe
CD41 T-cell loss, and SAIDS (Joag et al., 1997a). A
second pathogenic chimera, SHIV89.6P, was derived by
serial transfusion of peripheral blood from a rhesus ma-
caque initially infected with the molecular clone SHIV89.6
(containing the env gene from HIV-189.6) (Reimann et al.,
1996a). Animals that received SHIV89.6P-infected blood
exhibited CD4 lymphopenia and SAIDS; in contrast, iv
inoculation with cell-free SHIV89.6P into rhesus ma-
caques induced CD41 T-cell loss and persistent infec-
tion, but no disease (Reimann et al., 1996a). Although,
SHIV89.6 can establish infection by the mucosal route (Lu
et al., 1996), IVAG challenge with SHIV89.6P has not been
reported. The last of the pathogenic SHIV described
SHIVMD14, where cell-free iv inoculation induces high
plasma viremia, sustained CD41 T-cell depletion, and
immunodeficiency in pig-tailed macaques, but not in
rhesus or cynomolgus monkeys (Shibata et al., 1997).
We have previously described the iv infection of a
rhesus macaque with the molecular clone SHIVSF33, con-
taining the env sequences from HIV-1SF33 (Luciw et al.,
1995). After 72 weeks of infection the animal exhibited an
increase in plasma viral load with a concomitant de-
crease in the percentage of CD41 peripheral blood
mononuclear cells (PBMC) (Cheng-Mayer, 1996). The
macaque succumbed to disease and was sacrificed af-
ter 132 weeks with SAIDS diagnosis confirmed at nec-
ropsy. Transfusion of whole blood collected from this
animal at week 104 caused SAIDS in two juvenile rhesus
macaques. Additionally, iv inoculation of newborn ma-
caques with virus recovered from PBMC at week 104,
designated SHIVSF33A (adapted), induced rapid CD4
1
cell loss and SAIDS (Luciw, 1997). In this study we report
the initial characterization of IVAG cell-free SHIVSF33A
infection as an experimental model for heterosexual HIV
transmission. We found that pathogenic CXCR4-utilizing
SHIVSF33A variants crossed the cervicovaginal mucosa
and established persistent infection in the macaque
host. During acute infection, high levels of plasma vire-
mia and substantial decreases in the CD41 T-cell subset
were noted. In addition, we have analyzed the genotype,
phenotype, and pathogenicity of the viral quasispecies
that established transvaginal infection in order to further
understand the properties associated with IVAG mucosal
transmission and pathogenic outcome of SHIVSF33A in-
fection.
RESULTS
Acute infection after IVAG exposure to SHIVSF33A
Four rhesus macaques were inoculated IVAG with 104
TCID50 of SHIVSF33A. Within 1 week of single exposure,
high levels of viremia were detected in the plasma of
each animal, as demonstrated by bDNA analysis (Fig.
1A). Plasma viral RNA peaked at 2 weeks postinoculation
and fell below the detection limit of 104 copies/ml there-
after, except for an increase in plasma viremia at week
32 in Rh1546. Despite receiving identical inocula, marked
differences were noted between animals in terms of their
peak viral load, which varied by 2 logs among the four
animals. Plasma samples were also analyzed for p27gag
antigenimia at time points corresponding to bDNA and
FACS analysis (Table 1). Viral antigen was detected in
three of the animals at 2 weeks after virus inoculation.
Macaque Rh1546, the animal that had the lowest levels
of cell-free viremia and a more moderate loss in the
CD41 T-cell population during acute infection, had no
detectable p27gag antigen in plasma samples up to 36
weeks postinfection. The frequency of SHIVSF33A-in-
fected PBMC also peaked at 2 weeks postinfection (Ta-
ble 1), but much less variation was noted among the
animals. Coincident with peak viral loads, a dramatic
decrease in the absolute number of circulating CD41
T-cells was observed, denoting replication of cytopathic
virus within the macaque host (Fig. 1A). The absolute
number of CD41 PBMC, however, began to increase
slowly around 24 weeks and this increase was main-
tained when last examined at 36 weeks in three of the
four animals (Rh1542, Rh1544, and Rh1548) (Fig. 1A). In
an attempt to define potential mechanisms for this re-
population of peripheral CD41 T-cells, the percentage of
naive cells (phenotype CD31/CD41/CD45RA1/CD62L1)
within the total CD31/CD41 T-cell population over the
course of infection was determined by staining with a
panel of monoclonal antibodies. Using this cocktail of
antibodies, over 90% of cells present in rhesus macaque
cord blood were stained (Harouse, 1997). In three of the
macaques (Rh1542, Rh1544, and Rh1548), we observed a
transient increase in the percentage of naive T-cells at 2
weeks, followed by a drop in this population at 4 weeks
postinoculation (Fig. 1B). After 20 weeks, the percentage
of naive cells within the CD41 T-cell subset was regen-
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erated in these three animals. When last examined at 36
weeks postinoculation, the naive CD41 T-cell subset
was repopulated at a higher percentage than baseline
(Fig. 1B). Macaque Rh1546, which showed a more mod-
est drop in the CD41 T-cell subset, showed only a mod-
erate increase in CD41 naive T-cells (Figs. 1A and 1B).
Persistence of viral infection
Three approaches were employed to demonstrate per-
sistent infection in the macaques. First, the frequency of
SHIVSF33A-infected cells was determined by culturing pu-
rified PBMC from the IVAG-infected animals with
CEMx174 cells and visually monitoring cultures for cyto-
pathic changes indicative of viral infection (Table 1). After
the primary viremia phase, the frequency of infected
PBMC decreased dramatically and SHIVSF33A-infected
cells were intermittently detectable thereafter. In a sec-
ond cell culture system, 3–5 3 106 PBMC from the
infected macaques were cultured with human PBMC,
and cultures were monitored for the presence of viral
antigen by antigen capture ELISA (data not shown). In-
fectious virus was rescued from macaque PBMC at most
time points examined. In addition to cell culture assays,
DNA was isolated from purified PBMC and analyzed for
FIG. 1. (A) Absolute CD41 (n) and CD81 (F) cell counts in peripheral blood from macaques Rh1542, Rh1544, Rh1546, and Rh1548. Secondary Y
axis indicates plasma viral RNA () levels as determined by the branched DNA (bDNA) analysis (see Materials and Methods). Baseline values of 104
copies/ml indicate data points that are below the detection limit. (B) To identify the naive cell population within the CD3/CD41 T-cell population,
Ficoll-purified PBMC were stained with antibodies that recognize the CD3, CD4, LECAM, and LCA molecules. Rh1542 (n), Rh1544 (F), Rh1546 (),
Rh1548 (}).
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the presence of proviral DNA. Using PCR amplification
assays, we detected HIV-1 env sequences in each of the
four animals at all time points collected (Table 1). These
results clearly demonstrate that infectious proviral DNA
sequences were maintained in the PBMC of the four
SHIVSF33A-infected animals 36 weeks after a single IVAG
exposure.
Analysis of virus transmission and viral quasispecies
by heteroduplex tracking assay (HTA)
Although each animal was infected with the identical
viral inoculum, selection and/or amplification of variants
during mucosal transmission may contribute to differ-
ences in viral replication and pathogenesis within the
newly infected animals. This prompted us to examine
whether the viral quasispecies transmitted across the
genital mucosa were comparable among the four ani-
mals. To this end, we utilized the HTA, a sensitive system
that allows rapid determination of the complexity within
the viral quasispecies in each animal. HTA analysis per-
mits visualization of viral diversity due to the sequence-
specific retarded mobilization of DNA heteroduplexes in
a polyacrylamide gel (Delwart et al., 1994, 1993). To
estimate the level of genetic diversity within the env
region of the transmitted SHIVSF33A quasispecies, provi-
ral sequences from PBMC were coamplified by nested
PCR (to ensure correct population sampling two inde-
pendent PCR reactions were performed and compared
for each sample) (Delwart and Gordon, 1997). The mini-
mum number of env variants present in PBMC was
identified by the annealing of PCR-amplified V3-V5 frag-
ments to a radiolabeled single-stranded fragment gen-
erated from a reference strain, HIV-1SF128A, that has 11%
sequence diversity from SHIVSF33A-derived clones in the
region of env analyzed. As shown in Fig. 2, the viral
inoculum, SHIVSF33A, is a relatively homogeneous mix of
species, composed of one major and one minor env
TABLE 1
Analysis of SHIVSF33A Infection in Rhesus Macaques
Week
Plasma p27gag antigen (ng/ml)a Frequency of infected PBMC (per 106 cells)b
Rh1542 Rh1544 Rh1546 Rh1548 Rh1542 Rh1544 Rh1546 Rh1548
1 2 2 2 2 n.d., 1c,d n.d., 1 n.d., 1 n.d., 1
2 3.9 17.3 2 0.2 20000, 1 60000, 1 50000, 1 10000,1
4 2 2 2 2 10, 1 20, 1 10, 1 10, 1
6 2 2 2 2 10, 1 20, 1 10, 1 10, 1
8 2 2 2 2 10, 1 10, 1 ,1, 1 ,1, 1
12 2 2 2 2 ,1, 1 10, 1 10, 1 ,1, 1
16 2 2 2 2 ,1, 1 10, 1 10, 1 ,1, 1
20 2 2 2 2 ,1, 1 ,1, 1 ,1, 1 ,1, 1
24 2 2 2 2 ,1, 1 10, 1 ,1, 1 ,1, 1
28 2 2 2 2 ,1, 1 ,1, 1 ,1, 1 ,1, 1
32 2 2 2 2 ,1, 1 ,1, 1 ,1, 1 ,1, 1
36 2 2 2 2 ,1, 1 ,1, 1 ,1, 1 ,1, 1
a Plasma was clarified from EDTA-treated peripheral blood and analyzed for the presence of viral antigen using an antigen capture ELISA (Cellular
Products, Inc.). Negative samples (2) had p27gag values below 62.5 pg/ml.
b Tenfold serial dilution’s of macaque PBMC were cultured with 1 3 105 CEMx174 cells for 10–14 days. Cultures were visually monitored for
cytopathological changes.
c n.d., not done.
d (1) Indicates that viral env sequences were detected in DNA isolated from (2.5 3 105) PBMC.
FIG. 2. Heteroduplex tracking assays (HTA) of viral species amplified
from PBMC of vaginally infected macaques. Analysis of a PCR-gener-
ated 648-bp region of the HIV-1 env gene containing V3, V4, and V5
domains. Viral species were tracked using a single-stranded 33P end-
labeled DNA fragment derived from HIV-1SF128A plasmid DNA. For each
animal sample two independent PCR amplifications were analyzed.
SHIVSF33A represents the RT–PCR product from the viral inoculum used
to infect macaques. The presence of a homoduplex indicates that a
sequence is .98% homologous to the tracking DNA. The more diver-
gent a viral species is from the probe, the slower the mobility of the
DNA duplex. Lanes: 1 and 2, Rh1542; 3 and 4, Rh1544; 5 and 6, Rh1546;
7 and 8, Rh1548; 9 and 10, SHIVSF33A; 11, reference DNA HIV-1SF128A; 12,
single-stranded SF128A DNA probe; the presence of homoduplex in
this lane indicates incomplete purification of ssDNA.
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variant. However, viral species that represent less than
2% of the total virus population may not be detected
using the assay conditions described (data not shown).
Examination of the env quasispecies present in the IVAG
animals after 2 weeks demonstrated differences in viral
genotype complexity among the four animals. Env se-
quences amplified from the PBMC of both Rh1542 and
Rh1548 formed two major heteroduplexes with SF128A
reference DNA sequences, indicating that a minimum of
two env variants were present at 2 weeks. Macaques
Rh1544 and Rh1546 harbor at least four major env vari-
ants that have similar mobility in polyacrylamide gel. The
fastest migrating heteroduplexes formed when Rh1542,
Rh1544, or Rh1546 samples are complexed with SF128A
probe appear to be similar in mobility to the major env
variant present in the viral inoculum. Nevertheless, each
of the four IVAG-challenged animals, in particular
Rh1548, harbor viral sequences within their PBMC that
are not readily detected in the inoculum. Specifically, the
slower migrating heteroduplex (Fig. 2, lanes 1–8) is not
present as a major env variant within the viral inoculum.
Since similar results were obtained with PBMC isolated
1 week after inoculation (data not shown), it is unlikely
that variants present in the IVAG-infected animals and
not detected in the viral inoculum arose independently in
each of the animals from in vivo evolution during the
short period between transmission and sampling. Thus,
these data show that, similar to HIV-1 and SIV, mucosal
transmission of SHIVSF33A results in the preferential
transport or selective amplification of minor variants
(Trivedi et al., 1996; Zhu et al., 1996).
Coreceptor utilization of IVAG-transmitted viruses
Several studies have shown that the HIV-1 sequences
amplified shortly after viral transmission are relatively
homogenous compared to the diverse quasispecies
found within the transmitter and are associated with
viruses that are macrophage-tropic (MT) and non-syncy-
tium inducing (NSI) (Wolfs et al., 1992; Wolinsky et al.,
1992; Zhu et al., 1993, 1996). These observations have
lead to the hypothesis that a block in viral transmission
may occur at the mucosal barrier to permit the preferen-
tial transmission of MT/NSI viruses. With the identifica-
tion of the CCR5 chemokine receptor as a major core-
ceptor for MT/NSI viruses (Alkhatib et al., 1996; Choe et
al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic et
al., 1996), it was of interest to determine whether the
selective force for preferential transmission of some vari-
ants within the SHIVSF33A quasispecies is related to the
ability of these viruses to utilize the CCR5 coreceptor. To
examine the coreceptor phenotype in SHIVSF33A viruses
that had been selected in vivo via mucosal transmission,
we cultured virus from macaque PBMC isolated 2 weeks
after transmission and tested these viral populations for
their ability to productively infect cell lines expressing the
CXCR4 or CCR5 coreceptors (Alkhatib et al., 1996; Choe
et al., 1996; Deng et al., 1996; Doranz et al., 1996; Dragic
et al., 1996; Feng et al., 1996). Assays that examined
steps early (PCR, data not shown) and late (viral p27gag
antigen production) in the viral life cycle were used to
confirm viral entry. The inoculum, SHIVSF33A, as well as
virus cultured from PBMC of IVAG-exposed macaques
efficiently used CXCR4 as a coreceptor for retroviral
entry. These results indicate that CXCR4-utilizing viruses
were not restricted in transport across the cervicovaginal
mucosa in this model system (Table 2). In contrast to
CXCR4, differences in the ability to use the CCR5 protein
as a coreceptor were observed among the animals.
Specifically, viruses amplified from Rh1548week2 were
able to infect U87/CD4 cells stably expressing either
CXCR4 or CCR5 molecules. Interestingly, the env variants
amplified from Rh1548 2 weeks after transmission were
distinct from those of the other macaques, as demon-
strated by HTA (Fig. 2); however, preliminary sequence
analysis of envelope clones generated from Rh1548week2
did not identify specific amino acid changes within the
V3-V5 regions that could be associated with CCR5 us-
age. Additionally, we were not able to infect cell lines
expressing the CCR1, CCR2b, CCR3, CCR4, BONZO/
STRL33, or BOB/gpr15 proteins with any of the
SHIVSF33A-derived viruses (data not shown) (Doranz et
al., 1997; Farzan et al., 1997).
In vivo serial transfer of IVAG selected variants
The transient nature of the plasma viremia and CD41
T-cell loss in the IVAG-infected animals suggested that
weakly pathogenic variants may have been transmitted
across the vaginal mucosa. To assess the virulence of
variants within the IVAG-transmitted quasispecies, whole
TABLE 2
Infection of Cell Lines Expressing Chemokine Receptors
with IVAG-Transmitted Viruses
Virusa U87/CD4/pBABEb U87/CD4/CXCR4 U87/CD4/CCR5
Rh1542week2 ,.01 1.56 ,.01
Rh1544week2 ,.01 0.31 ,.01
Rh1546week2 ,.01 0.34 ,.01
Rh1548week2 ,.01 0.18 0.43
SHIVSF33 13.25 369.82 9.81
SHIVSF33A 10.04 376.57 9.75
SHIVSF162 8.32 6.94 54.79
a Two weeks after mucosal infection PBMC were separated from
EDTA-treated blood and cultured with HIV-1-negative human PBMC
stimulated with SEB and IL-2. Cultures were monitored for the produc-
tion of p27gag antigen production; cell-free, viral supernatants were
stored at 280°C.
b Culture supernatants were collected 5 days after infection and
samples were analyzed for p27gag antigen (ng/ml) by capture ELISA
(Cellular Products, Inc.). Values are representative of 1/3 independent
experiments.
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blood obtained during peak acute viremia (Fig. 1, Table 1)
from animals Rh1542 and Rh1544 was transfused into re-
cipient animals (Rh1542 into Rh1408; Rh1544 into Rh1406
and Rh1410, Fig. 3). Transfused animals were monitored for
signs of infection including absolute number of CD41 and
CD81 cells, plasma viremia, and frequency of infected
PBMC, as described for the IVAG animals. The transfused
macaques suffered a more profound loss in the CD31/
CD41 T-cell subset when compared to the IVAG-infected
animals, and moreover, this cell population did not rebound
over time (Fig. 4, Table 3). Peak plasma viremia occurred
within the first 2 weeks of exposure, with values in the
same range as those of the donor IVAG animals. However,
in general the viral set point in the iv animals was greater
than that of the IVAG animals, as cell-free virus was de-
tected in the plasma of iv animals at most timepoints ex-
amined (Fig. 4). Within 3 weeks of inoculation all transfused
animals developed humoral immune responses to both
HIV-1 and SIV proteins, as detected in a solid-phase immu-
noassay (Harouse et al., 1998). Additionally, infectious virus
and viral nucleic acids were consistently detected in puri-
fied PBMC cultures, as described for the IVAG animals.
Using HTA to examine the viral quasispecies present in
recipient macaques, we found that the dominant env spe-
cies present in PBMC of recipient animals 1 week after
transfusion were indistinguishable from env species
present in donor animals Rh1542 and Rh1544 at the time of
transfusion (Fig. 5). Transfused animal Rh1410, which
showed the highest levels of postacute viral replication (Fig.
4), was euthanized at 29 weeks due to rapid weight loss
and dehydration. Necropsy findings included pleuritis,
pneumonia, and lymphadenopathy. Virus was cultured from
both peripheral and internal lymph nodes postmortem. Ma-
caque Rh1406, which received the identical inoculum as
Rh1410, demonstrated significantly diminished levels of
both acute and postacute viremia. This observation indi-
cates that, similar to HIV-1 infection in humans and the
SIV/macaque model, host-specific factors involved in the
establishment of the viral replication set point in the acute
and postacute phases of infection influence the ultimate
disease course (Hirsch et al., 1997; Lifson et al., 1997;
Mellors et al., 1996; Nowak et al., 1997; Watson et al., 1997).
Combined, these results suggest that a pathogenic virus
within the SHIVSF33A quasispecies was transmitted through
IVAG inoculation of Rh1544 and subsequently transfused
into Rh1410, indicating that the slower disease progression
in Rh1544 is not due to the lack of pathogenic variants, but
rather due to host-specific responses that contain disease
progression.
DISCUSSION
Four sexually mature Macaca mulatta were exposed
IVAG to cell-free SHIVSF33A and longitudinal samples
FIG. 3. IVAG transmission of SHIVSF33A into rhesus macaques, fol-
lowed by serial transfusion of whole blood into naive animals. SAIDS,
animal Rh1410 was euthanized at 29 weeks posttransfusion.
FIG. 4. Absolute CD41 (n) and CD81 (F) cell counts in peripheral blood from macaques Rh1406, Rh1408, and Rh1410 that were transfused with
whole blood from IVAG-infected animals. Secondary Y axis indicates plasma viral RNA () levels as determined by branched DNA analysis (see
Materials and Methods).
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collected from each animal were analyzed in virologic
and immunologic assays. A persistent infection was es-
tablished in all four rhesus macaques exposed to a
single dose of SHIVSF33A (10
4 TCID50) via atraumatic
intravaginal inoculation. In each of the animals, peak
virus production occurred within 2 weeks of virus expo-
sure, as determined by plasma viremia, antigenemia,
and cell-associated viral loads (Fig. 1A and Table 1). The
kinetics of viral transmission and dissemination were
similar to those described by Joag et al. (1997a) after
IVAG inoculation with SHIVKU in pig-tailed macaques and
to IVAG SIV infection in rhesus macaques where the
acute viremic state occurs within the first weeks after
infection (Miller et al., 1989). Host-specific antiviral hu-
moral responses were first detected at 4 weeks postin-
oculation and increased in both specificity and strength
thereafter (Harouse et al., 1998). In agreement with in-
fections reported with other pathogenic SHIVs, dramatic
decreases in the absolute number of CD41 T-cells
present in the peripheral blood were observed shortly
after IVAG inoculation with SHIVSF33A coincident with
peak plasma viremia and antigenemia (Fig. 1A). A corre-
lation between the degree of CD41 T-cell loss and
plasma viremia was noted, indicating replication of cy-
topathic virus. Each of the four rhesus macaques in-
fected with SHIVSF33A via the IVAG mucosal route dem-
onstrated a regeneration in the CD41 T-cell population,
although to different extents. Rebound in CD41 T-cell
subset has also been reported in some animals infected
by cell-free SHIV89.6P and SHIVMD14 (Reimann et al.,
1996a; Shibata et al., 1997), but the underlying mecha-
nism for CD41 T-cell recovery was not addressed in
these other studies. In our study, we asked whether the
recovery in the absolute number of CD41 T-cells in the
peripheral blood after acute SHIVSF33A infection was due
to either redistribution of preexisting memory T-cells
from various lymphoid compartments or from the regen-
eration of the CD41 population via thymopoiesis (Mack-
all et al., 1995, 1993). The restoration of the CD41 naive
cell subset that we observed in the SHIVSF33A IVAG-
infected animals suggests that the underlying mecha-
nism of CD41 T-cell regeneration is at least partially due
to a thymic-dependent pathway (Fig. 1B) (Mackall et al.,
1995; Mackall et al., 1993; Mackay, 1991). The average
age of the IVAG-exposed animals at the initiation of this
study was 21
2
years, an age when rhesus macaques are
likely to have an active thymus. Infectious virus was
cultivated from the PBMC of each macaque at time
points up to 36 weeks after infection, indicating that
intact proviral DNA is harbored within this population of
cells, albeit at a low level. The presence of infected
PBMC at 9 months demonstrates that either T-cells are
TABLE 3
Absolute Number of CD41 Cells in Peripheral Blooda of SHIVSF33A-Infected Macaques
Week Rh1542 Rh1544 Rh1546 Rh1548 Rh1406 Rh1408 Rh1410
0 1646 1639 1780 914 933 2296 794
1 1675 1675 1196 1090 382 1224 202
2 545 216 1052 902 99 625 58
4 510 184 1055 412 124 433 41
6 364 192 1095 342 123 304 41
8 516 219 618 247 99 479 27
12 497 316 768 78 48 205 16
16 757 391 1076 366 43 300 17
20 393 332 811 245 43 533 15
24 419 550 641 611 21 310 19
28 1251 730 2320 1090 n.d.b n.d. 9c
32 1078 431 737 1259 13 197
36 1049 627 679 850 9 446
a The absolute number of CD41 cells/ml peripheral blood was determined using TruCount Absolute Count Tubes (Becton–Dickinson; see Materials
and Methods).
b n.d., not done.
c Animal Rh1410 sacrificed at week 29 with SAIDS diagnosis.
FIG. 5. HTA analysis comparing env sequences harbored within
PBMC of donor (Rh1542week2; Rh1544week2) and recipient (Rh1408week1;
Rh1406week1 and Rh1410week1) macaques. A
33P-labeled, dsDNA
HIV-1SF162 reference strain was used for heteroduplex tracking.
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continually infected in the IVAG-inoculated macaques
and hence low levels of viral replication are ongoing or
alternatively that a population of long-lived infected cells
exists within the PBMC.
The establishment of IVAG infection of macaques by
SHIVSF33A allowed us to evaluate the viral species that
were preferentially transferred across the cervicovaginal
mucosa (Fig. 2). This analysis of env variants present in
PBMC 2 weeks after IVAG inoculation with SHIVSF33A
showed selection of minor variants from within the inoc-
ulating quasispecies similar to perinatal, homosexual,
and heterosexual transmission of HIV-1 and models of
SIV sexual transmission in macaques (Amedee et al.,
1995; Trivedi et al., 1996, 1994; Wolfs et al., 1992; Wolinsky
et al., 1992; Zhu et al., 1993, 1996). The population of env
species varied among the four animals at 2 weeks after
infection, indicating that host-specific factors contributed
to the selection of the quasispecies transmitted or am-
plified in the newly infected macaque host. However, a
minor variant of similar mobility on HTA was present in
each of the four animals. These data suggest that, sim-
ilar to sexual transmission of HIV-1 in humans, IVAG
infection of macaques with SHIVSF33A is a highly complex
process involving multiple host and viral factors (Fauci,
1996; Zhu et al., 1996). Whether specific SHIVSF33A vari-
ants are preferentially transmitted across the mucosal
membrane, perhaps due to host-specific differences in
coreceptor expression, or whether they are selectively
amplified at or near the site of transmission, perhaps due
to host-specific differences in immune response, cannot
be distinguished in this study. As these mechanisms are
not mutually exclusive, it is possible that both function to
create a diverse viral repertoire in the newly infected
host. Detailed sequence analysis of env clones derived
from these animals and comparison with those present
in animals infected intravenously with SHIVSF33A, to-
gether with the development of infectious molecular
clones, will be necessary to identify a putative motif(s)
that might be associated with IVAG transmission.
To assess whether selective transmission can be at-
tributed to coreceptor utilization, we examined the core-
ceptor phenotypes of viruses that had been selected
through the genital mucosa (Table 2). Viruses within the
SHIVSF33A inoculum were found to preferentially utilize
the CXCR4 protein for viral entry in vitro. After short-term
in vitro culture in human PBMC, viruses isolated from the
PBMC of each macaque also replicated in cell lines
expressing CXCR4, while only virus isolated from Rh1548
utilized both the CXCR4 and CCR5 molecule as corecep-
tors for infection. Cell lines engineered to express the
chemokine receptors CCR1, CCR2b, CCR3, BONZO/
STRL33, or BOB/gpr15 were not susceptible to infection
by any of the SHIVSF33A-derived viruses (data not shown).
It is interesting that CCR5 usage did not appear to be
necessary for genital transmission of SHIVSF33A, since
the majority of isolates found early after HIV-1 infection in
humans are CCR5 specific. Although macaques express
a CXCR4 homologue, this protein is not used as a core-
ceptor for SIV; however, the simian CXCR4 protein can
function as coreceptor for the HIV-1 envelope in vitro
(Chen et al., 1997). It is possible that cell-free SHIVSF33A
utilizes a hitherto unidentified coreceptor expressed in
the cervicovaginal mucosa of rhesus macaques. Alter-
natively, the conformation of coreceptors expressed in
cell lines may not be identical to their native conforma-
tion in the target cells of the female genital tract. Current
studies are underway to determine whether there is a
dual-tropic virus, similar to HIV-189.6, or whether indepen-
dent viruses that use either CXCR4 or CCR5 are present
in the Rh1548 quasispecies (Doranz et al., 1996).
The transient nature of plasma viremia and CD41
T-cell loss, and the apparent absence or delay in disease
onset in the IVAG-exposed animals, prompted us to de-
termine whether a pathogenic variant(s) present in the
original SHIVSF33A inoculum was selected against upon
IVAG transmission. Our study in which whole blood from
the IVAG animals obtained 2 weeks postinoculation was
transfused into naive recipients strongly suggests that
virulent species within the SHIVSF33A virus crossed the
vaginal mucosa and established infection in the ma-
caque host. Persistent plasma viremia accompanied by
profound CD41 T-cell loss were noted immediately in the
transfused animals and SAIDS developed in one animal,
Rh1410. Although, it is formally possible that a virus with
enhanced pathogenicity arose de novo in Rh1410, this
animal established a high viral set point and low CD41
T-cell number shortly after transfusion, consistent with
the transfused animal having been directly infected with
a pathogenic virus that was present in the donor Rh1544
(Fig. 4). This is further supported by HTA analysis of the
virus in the donor Rh1544/recipient Rh1410 pair, where
mobility in heteroduplex tracking assays of env frag-
ments amplified near the time of transfusion were indis-
tinguishable in the donor/recipient pair (Fig. 5). These
results suggest that differences in disease course be-
tween IVAG and serially transfused animals arise from
host-specific responses and not because a less patho-
genic virus is present in the IVAG-infected animals. This
is additionally supported by observations that transfu-
sion of whole blood collected from Mmu25814 at week
104 into two naive juvenile macaques resulted in CD41
T-cell loss and SAIDS at 32 and 52 weeks posttransfu-
sion (Cheng-Mayer, 1996), and two newborn rhesus ma-
caques that were infected iv with cell-free SHIVSF33A
demonstrated a severe decline in the CD41 T-cells in
both peripheral blood and lymph node tissue. These
animals were subsequently sacrificed at 4 and 32 weeks
due to SIV-related disease (Luciw, 1997). Combined,
these results suggest that the route of virus exposure
alters disease course in the SHIVSF33A-infected animals,
possibly due to a more effective immune response in the
mucosally exposed animals. As the inocula were not
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identical between the IVAG and transfused animals, fur-
ther studies to directly examine this issue will be valu-
able in understanding the role of transmission route in
viral pathogenesis.
Two interesting conclusions flow from these findings.
First, IVAG-challenged macaques do not progress or
progress slowly to clinical disease despite the presence
of pathogenic SHIVs in their blood, as demonstrated by
transfusion studies. Since mucosal exposure leads to
local production of antibodies and immunological mem-
ory, which are important in the defense against patho-
gens that infect the uritogenital tract, this system is
therefore highly suitable for dissecting out those host
factors that can favorably modulate the course of patho-
genic SHIV infection. Second, this system apparently
shows a different disease course depending upon
whether viral challenge is by the IVAG or iv route. This is
illustrated most clearly by the comparable peak plasma
viral titers in the Rh1544/Rh1410 pair. It has been shown
that the level of peak plasma viremia following SIV chal-
lenge correlated with the level established in the post-
acute phase of infection and is crucial with regard to
eventual disease progression (Hirsch et al., 1996; Lifson
et al., 1997), yet these two animals with comparable peak
levels of a highly related if not identical virus differ in
disease outcome depending upon the route of infection.
Clearly, a more extensive investigation of this difference
must be done to shed light on mucosal factors that can
affect disease outcome. It has already been suggested
that mucosal immune responses occurring near the site
of transmission, responses that are absent in iv expo-
sure, prevent disease onset in HIV-exposed seronega-
tive individuals (Mazzoli et al., 1997).
In summary, we have shown that pathogenic, CXCR4-
utilizing SHIVSF33A variants can penetrate the cervico-
vaginal mucosa of rhesus macaques and establish per-
sistent infection. Since an efficacious HIV-1 vaccine will
likely need to induce host immune responses near the
site of transmission (i.e., the cells of the genital tract and
draining lymph nodes) in order to prevent systemic
spread of virus in the newly infected host, animal models
that faithfully mimic sexual transmission of HIV-1 are
essential tools in vaccine development. The SHIV/IVAG
transmission model described here displays many of the
characteristics of sexual transmission of HIV-1, and
hence its continued characterization should pave the
way for its use in assessing vaccine and antiviral po-
tency.
MATERIALS AND METHODS
Intravaginal and intravenous inoculation of rhesus
macaques
Four juvenile rhesus macaques, M. mulatta, were in-
oculated IVAG with 104 TCID50 of cell-free SHIVSF33A
(Luciw et al., 1995; Miller et al., 1989). In serial transfer
studies 5 ml of ACD whole blood obtained from the donor
animal 2 weeks after IVAG exposure was inoculated
intravenously into naive recipients. Prior to inoculation
macaques were determined to be serologically negative
for SIV, D-type simian retroviruses, and STLV-1. At the
time of inoculation animals averaged 21
2
years of age, 5
kg, in the IVAG group and 8 years, 9 kg, in the transfusion
group. Animals were maintained individually housed in a
United States Department of Agriculture (USDA)-in-
spected and -approved facility.
Cell culture
PBMC were separated from EDTA-treated whole blood
by Ficoll gradient centrifugation (Lymphocyte Separation
Media, Bio Whittaker, Walkersville, MD). Macaque PBMC
were stimulated with 5 mg/ml staphylococcal enterotoxin
B (SEB, Sigma Biochemical, St. Louis, MO) and 100 U/ml
recombinant IL-2 (Hoffman–LaRoche). Human PBMC
isolated from seronegative donors were stimulated with
3 mg/ml phytohemagglutinin (PHA) (Sigma Biochemical)
and 100 U/ml IL-2. Both cell types were cultured in RPMI
1640 supplemented with 10% fetal calf sera (FCS),
L-glutamine, and penicillin/streptomycin. Lymph node
mononuclear cells (LNMC) were mechanically dissoci-
ated from lymph node biopsy tissues, followed by Ficoll
gradient centrifugation as above. CEMx174, a CD41 T-
cell/B-cell hybrid cell line (Howell et al., 1982), was main-
tained in RPMI/10% FCS, L-glutamine, and penicillin/
streptomycin. U87MG.CD4 cells (a gift of Dr. Nathaniel
Landau) stably transfected with either pBABE, pBABE/
CXCR4, or pBABE/CCR5 were propagated in DMEM sup-
plemented with 10% FCS, glutamine, and penicillin/strep-
tomycin and maintained under puromycin selection as
previously described (Deng et al., 1996).
Virus isolation and TCID50
Virus was recovered from macaque PBMC (3–5 3 106
cells) by cultivation with an equal amount of PHA/IL-2-
stimulated human PBMC obtained from seronegative
donors. Cultures were maintained for 10–14 days and
monitored for viral antigen production, and cell-free viral
supernatants were stored in 1.0-ml aliquots at 280°C
until use. Viral p27gag antigen in the virus stocks was
quantitated by antigen capture enzyme-linked immuno-
adsorbent assay (ELISA, Cellular Products Inc., Buffalo,
NY). To determine the frequency of infected PBMC, 1 3
105 CEMx174 cells were cultured with serial 10-fold dilu-
tion of stimulated macaque PBMC. Cultures were visu-
ally monitored for cytopathological changes and the end
point was calculated.
In vitro viral infections
For in vitro virus infection studies, 3 3 104 U87/CD4
cells stably expressing CXCR4 or CCR5 molecules were
plated in a 24-well plate and allowed to adhere overnight
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(U87/CD4 cells transfected with vector pBABE lacking
insert DNA served as control cells). Culture medium was
removed, and cells were washed 32 in PBS and ex-
posed to viral supernatants containing 10–30 ng/ml of
p27gag antigen. Infections were maintained at 37°C for
4 h, after which inoculum was removed, and cultures
were washed 33 in Hanks’ buffered saline solution
(HBSS) and maintained in culture media as described
above. Twenty-four hours after infection cultures were
again washed 33 in HBSS. Five days after infection both
culture supernatants and cells were collected and ana-
lyzed for either viral antigen or viral nucleic acids, re-
spectively.
Detection of plasma antigen
Plasma p27gag antigen was assayed using the RETRO-
TEK SIV-1 p27gag Antigen ELISA (Cellular Products Inc.)
according to the manufacturer’s instructions.
Flow cytometry staining and analysis
The following human monoclonal antibodies (mAb)
were used: Leu-5b-FITC (fluorosceine isothiocyanate),
Leu-3a-PE (phycoerythrin), Leu-2a-PerCP (peridinin chlo-
rophyll protein), Leu-8-PE, and Leu-18-FITC that recog-
nize the CD2, CD4, CD8, CD62L (leukocyte endothelial
cellular adhesion molecule LECAM) and CD45RA (leu-
kocyte common antigen, LCA) molecules, respectively
(Becton–Dickinson, San Jose, CA). The mAb FN-18-FITC,
which recognizes the monkey CD3 molecule, was also
used (Biosource Int., Camarillo, CA). Absolute CD4 and
CD8 cell counts were measured using TruCount Abso-
lute Count Tubes (Becton–Dickinson, Mountainview, CA)
according to the manufacturer’s instructions. Flow cy-
tometry analysis was performed using the FACS Caliber.
bDNA assay
Quantitative assays for the measurement of plasma
SHIV RNA were performed using a bDNA signal ampli-
fication assay (Dailey et al., 1995; Marx et al., 1996). This
assay is similar to the Quantiplex HIV-RNA assay (Pachl
et al., 1995) except that the target probes were designed
to hybridize with the pol region of viruses within the
SIVmac group of strains. Virion-associated RNA was
quantified after being pelleted from 1 ml of EDTA-treated
plasma (23.5 kg for 1 h at 4°C) by comparison with a
standard curve produced using serial dilution of cell-free
SIV-infected tissue culture supernatant. The quantifica-
tion of this standard curve was determined by com-
parison with purified, quantified, in vitro-transcribed
SIVmac239 pol RNA. The lower limit of sensitivity for this
assay was 104 copies of SIV RNA/ml of plasma.
Nucleic acid isolation
Total cellular nucleic acids were extracted from ma-
caque LNMC or PBMC using the DNA/RNA Isolation Kit
according to the manufacturer’s instructions (United
States Biochemical, Cleveland, OH). Viral RNA was iso-
lated from plasma or culture supernatant by pelleting the
virus contained in a 200-ml sample with a Heraeus 17RS
microcentrifuge at 23,550 g for 60 min at 4°C. Superna-
tant was removed, and the virion pellet was suspended
in 200 ml of Chiron lysis solution (Chiron Corp., Emery-
ville, CA) containing 1.5 mg/ml Proteinase K (Boeh-
ringer Mannheim, Indianapolis, IN). Samples were vor-
texed briefly and incubated at 56°C for 30 min. An equal
volume of phenol:chloroform (5:1) containing 40 ng/ml of
yeast tRNA (Sigma Corp., St. Louis, MO) was added to
each sample; samples were mixed gently and rocked at
room temperature for 15 min. Nucleic acids were precip-
itated from the aqueous phase by the addition of 0.7 vol
isopropanol followed by an incubation at 280°C. The
samples were washed in 70% ethanol, air dried, and
suspended in 25 ml nuclease-free dH2O. To remove con-
taminating viral DNA, 1 ml of RNasin (Promega, Madison,
WI), 2.8 ml 103 DNase buffer, and 1 ml of RNase-free
DNase 1 (Boehringer Mannheim, Indianapolis, IN) were
added, and samples incubated at 37°C for 20 min fol-
lowed by an inactivation step at 80°C. Viral RNA was
reverse-transcribed by the addition of 2.0 ml 103 buffer,
12 ml sample RNA, 1.2 ml 25 mM dNTP, 5.0 ml 50 mM
primer ED12 (see PCR methods for sequence) and 2.0 ml
of M-MuLV-RT (Boehringer Mannheim, Indianapolis, IN)
at 37°C for 30 min.
PCR
Viral DNA sequences encoding the HIV-1 env gene
were amplified using a nested PCR (nPCR) reaction as
described previously (Delwart et al., 1994; Delwart et al.,
1993). The first round primers, ED3 and ED14, corre-
spond to nucleotides (nt) 5537 to 5566 and 7509 to 7538,
respectively, of HIV-1IIIB clone BH-10. Second round prim-
ers were either ED5 and ED12 (used in molecular clon-
ing) that correspond to nt 6134 to 6159 and 7359 to 7388
or ES7 and ES8 (used in HTA analysis) that correspond to
nt 6579 to 6598 and 7225 to 7245. Each reaction con-
tained 10–100 ng template DNA, 1.5 mM MgCl2, 0.2 mM
each primer, 400 mM each dNTP, and 2.5 units of Taq
DNA polymerase (Boehringer Mannheim) in buffer con-
taining 2 mM Tris–HCl, 0.1 mM dithiothreitol, 10 mM
EDTA, and 10 mM KCl. Amplification was performed in a
Perkin–Elmer 9600 Thermocycler under the following
conditions: ED3/ED14 and ED5/ED12 (94°C for 60 s,
55°C for 60 s, 72°C for 2 min) for 5 cycles followed by 25
cycles (94°C for 30 s, 55°C for 45 s, 72°C for 1.5 min),
with a final 72°C extension of from 10 to 60 min; and
primer pair ES7/ES8 (94°C for 30 s, 48°C for 30 s, 72°C
for 1 min) for 5 cycles followed by 25 cycles (94°C for
30 s, 48°C for 30 s, 72°C for 45 s), with a final 72°C
extension of from 10 to 60 minutes.
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Heteroduplex tracking assay
HTA was performed as described previously for HIV-1
(Delwart and Gordon, 1997). Briefly, DNA extracted from
2.5 3 105 uncultured macaque PBMC was subjected to
thermocycling using a nested PCR protocol to amplify a
648-bp (V3-V5) fragment of HIV-1 env region (Delwart et
al., 1994; Delwart et al., 1993). For each time point two
independent DNA extractions and subsequent PCR am-
plifications were performed. One to four microliters from
the sample PCR mixtures was combined with 1
10
vol 103
annealing buffer (100 mM Tris, pH 7.5, 1 M NaCL, 50 mM
EDTA) and 104 cpm of 33P-labeled reference DNA probe.
The 33P-labeled double-stranded DNA tracking probe
was generated by amplifying a HIV-1 reference plasmid
with the second round primers ES7 and ES8 in the
presence of [a-33P]dATP, as described by Delwart et al.
(1993). The 33P-labeled single-stranded DNA tracking
probe was generated by amplifying a HIV-1 reference
plasmid with a 59 biotinylated primer, ES7, and a 59
33P-labeled primer, ES8. The radiolabeled ssDNA is sep-
arated from the biotin-labeled strand by use of magnetic
Dynabeads M280 coated with streptavidin followed by
denaturing the double-stranded DNA in 0.1 N NaOH
(Delwart and Gordon, 1997). The target/probe mixture
was heated to 95°C for 2 min followed by immediate
quenching on ice. Heteroduplexes formed between di-
vergent env sequences were resolved by electrophore-
sis through a 5% native polyacrylamide gel at 250 V for
3.5 h. Gels were vacuum dried gels and exposed to a
PhosphorImager plate (Molecular Dynamics, Sunnyvale,
CA) for signal detection and analyzed with ImageQuant
software system.
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